George M Shaw, MD | |
619 19th Street South, Birimingham, AL 35233 | |
(205) 934-6600 | |
Not Available |
Full Name | George M Shaw |
---|---|
Gender | Male |
Speciality | Internal Medicine - Hematology & Oncology |
Location | 619 19th Street South, Birimingham, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326066309 | NPI | - | NPPES |
051513422 | Other | AL | BLUE CROSS |
C74069 | Other | AL | VIVA |
000014745 | Other | AL | BLUE CROSS |
110016416 | Other | AL | RAILROAD MEDICARE |
3771 | Other | FL | FLORIDA MEDICAID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | 12060 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
George M Shaw, MD Po Box 55310, Birmingham, AL 35233 Ph: (205) 731-9701 | George M Shaw, MD 619 19th Street South, Birimingham, AL 35233 Ph: (205) 934-6600 |
News Archive
People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy where seizures emanate from one area of the brain, according to a Rutgers study.
Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.
NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced it has secured an exclusive worldwide license from Bioclassifier, LLC to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping.
Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.
› Verified 2 days ago